Search
Feed aggregator
Opinion: Biopharma Should Prioritize Research on the Economics of Therapies
Opinion: Biopharma Should Prioritize Research on the Economics of Therapies 3/27/2024
In an Evolving Market, HR Leaders Balance Business Needs with Employee Engagement
In an Evolving Market, HR Leaders Balance Business Needs with Employee Engagement 3/27/2024
Global study could change how children with multiple sclerosis are treated
A ground-breaking study - the largest of its kind globally - has found children with multiple sclerosis (MS) have better outcomes if treated early and with the same high-efficacy therapies as adults.
There are a limited number of therapies approved for children with MS, with only one considered to be of high-efficacy - meaning highly effective.
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension 3/26/2024
Viking Touts Promising Phase I Data for Weight-Loss Pill Candidate
Viking Touts Promising Phase I Data for Weight-Loss Pill Candidate 3/26/2024
Brazil and Caring Cross to Produce Affordable CAR-T, Stem Cell Gene Therapies
Brazil and Caring Cross to Produce Affordable CAR-T, Stem Cell Gene Therapies 3/26/2024
AstraZeneca’s Ultomiris Wins FDA Approval for Rare Autoimmune Disease
AstraZeneca’s Ultomiris Wins FDA Approval for Rare Autoimmune Disease 3/26/2024
Stoke’s Early-Stage Data for Genetic Epilepsy Drug Sends Stock Skyrocketing
Stoke’s Early-Stage Data for Genetic Epilepsy Drug Sends Stock Skyrocketing 3/26/2024
Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy
Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy 3/26/2024
BioNTech Hit with NIH Notice of Default Over COVID-19 Vaccine Royalties
BioNTech Hit with NIH Notice of Default Over COVID-19 Vaccine Royalties 3/26/2024
FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma 3/25/2024
Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease
Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease 3/25/2024
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline 3/25/2024
J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill
J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill 3/25/2024
FDA Authorizes Invivyd’s Pemgarda to Prevent COVID-19 in Immunocompromised People
FDA Authorizes Invivyd’s Pemgarda to Prevent COVID-19 in Immunocompromised People 3/25/2024
AbbVie Secures Full FDA Approval for ADC Elahere in Ovarian Cancer
AbbVie Secures Full FDA Approval for ADC Elahere in Ovarian Cancer 3/25/2024
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion 3/25/2024
Wegovy Cardiovascular Approval Furthers March into New Indications
Wegovy Cardiovascular Approval Furthers March into New Indications 3/25/2024
Epigenetic Editing Explodes on the Heels of Gene Editing Success
Epigenetic Editing Explodes on the Heels of Gene Editing Success 3/25/2024
World Pharma News
- Participants of pioneering CRISPR gene editing trial see vision improve
- Drug targeting RNA modifications shows promise for treating neuroblastoma
- Scientists track 'doubling' in origin of cancer cells
- Possible alternative to antibiotics produced by bacteria
- Kaposi sarcoma discovery could facilitate drug development